SCHEMBL3590446

SCHEMBL3590446

N[C@@H](CNC(=O)O)CC1CCCO1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.46
USP2 O75604 1/20 0.46
HPGD P15428 6/20 0.45
TP53 P04637 1/20 0.45
ALOX12 P18054 1/20 0.45
ANPEP P15144 1/20 0.44
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C9 P11712 1/20 0.41
PKM P14618 1/20 0.41
CYP2C19 P33261 1/20 0.41
HTT P42858 1/20 0.40
KDM4E B2RXH2 2/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MCL1 Q07820 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3590442 1.00 SMN1; SMN2 (0.46) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL27709407 1.00 SMN1; SMN2 (0.46) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL4975322 0.95 SMN1; SMN2 (0.42) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL3585503 0.95 SMN1; SMN2 (0.42) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL3585500 0.95 SMN1; SMN2 (0.42) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL20394606 0.77 ANPEP (0.42) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL7888410 0.75 USP2 (0.45) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL7366756 0.75 USP2 (0.45) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL7880579 0.75 USP2 (0.45) SMN1; SMN2USP2HPGDTP53ALOX12
SCHEMBL1711635 0.75 USP2 (0.45) SMN1; SMN2USP2HPGDTP53ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455521-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2013-06-04 US disclosed
US-7754737-B2 Diaminoalkane aspartic protease inhibitors VITAE PHARMACEUTICALS, INC. (US) 2010-07-13 US disclosed
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors VITAE PHARMACEUTICAL, INC (US) 2009-01-15 US disclosed
EP-1807078-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS Vitae Pharmaceuticals, Inc. (US) 2007-07-18 EP disclosed
WO-2006042150-A1 DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2006-04-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018103-A1 Diaminoalkane Aspartic Protease Inhibitors DNPEP, PEPD, ACE SMN1; SMN2 1477/4885USP2 692/4885HPGD 712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.